References

1.	Camí J, Farré M. Mechanisms of disease: drug addiction. N Engl J Med. 2003;349:975-986.
2.	Curie C. Welcome to the age of buprenorphine. Addiction Professional. 2003;1:12-15
3.	National Institute on Drug Abuse. Research Report Series: Heroin Abuse and Addiction. Bethesda, Md: National Institute on Drug Abuse, National Institutes of Health; 2000. NIH publication 00-4165.
4.	Fiellin DA, O'Connor PG. Office-based treatment of opioid-dependent patients. N Engl J Med. 2002;347:817-823.
5.	Leshner AI. Addiction is brain disease, and it matters. Science. 1997;278:45-47.
6.	Substance Abuse and Mental Health Services Administration. Model policy guidelines for opioid addiction treatment in the medical office form (sic) the Federation of State Medical Boards (FSMB) of the United States. Available at: http://www.samhsa.gov/centers/csat/content/dpt/model_policy.htm. Accessed September 23, 2003.
7.	Substance Abuse and Mental Health Services Administration. National Household Survey on Drug Abuse: Main Findings 1998. Rockville, Md: Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies; 2000.
8.	Substance Abuse and Mental Health Services Administration. Overview of Findings from the 2002 National Survey on Drug Use and Health. Rockville, Md: Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies; 2003. DHHS publication SMA 03-3774.
9.	Personal communication from the Center for Substance Abuse Treatment, March 5, 2004.
10.	Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomized, placebo-controlled trial. Lancet. 2003;361:662-668.
11.	Lavignasse P, Lowenstein W, Batel P, et al. Economic and social effects of high-dose buprenorphine substitution therapy. Ann Med Interne. 2002;153(suppl 3):1S20-1S26.